582
Participants
Start Date
September 30, 2012
Primary Completion Date
December 6, 2017
Study Completion Date
October 30, 2022
Crizotinib (PF-02341066)
For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels
U.Z. Gasthuisberg, Leuven
Institut Bergonie, Bordeaux
Centre Georges-Francois-Leclerc, Dijon
Centre Leon Berard, Lyon
Assistance Publique - Hôpitaux de Marseille - Hôpital de La Timone, Marseille
Institut Gustave Roussy, Villejuif
Helios Klinikum Bad Saarow, Bad Saarow
Universitaetsklinikum Carl Gustav Carus, Dresden
Universitaetsklinikum - Essen, Essen
Medizinische Hochschule Hannover, Hanover
UniversitaetsMedizin Mannheim, Mannheim
Klinikum Grosshadern Ludwig-Maximilians Univ. Muenchen, München
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Leiden University Medical Centre, Leiden
Radboud University Nijmegen Medical Centre, Nijmegen
Erasmus MC - Sophia kindersiekenhuis, Rotterdam
Oslo University Hospital - Radiumhospitalet, Oslo
Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw
National Cancer Institute, Bratislava
The Institute Of Oncology, Ljubljana
St. James's University Hospital, Leeds
University College Hospital, London
Christie NHS Foundation Trust, Manchester
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham
Collaborators (1)
Pfizer
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK